Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Chugai Seiyaku Kabushiki Kaisha
Chugai Seiyaku Kabushiki Kaisha A Japanese Corporation
Chugai Seiyaku Kabushiki Kaisha A Corporation Of Japan
Chugai Seiyaku Kabushiki Kaisha A Japanese Corporation_20100121
Chugai Seiyaku Kabushiki Kaisha_20100121
Chugai Seiyaku Kabushiki Kaisha_20131212
Chugai Seiyaku Kabushiki Kaisha_20100128
Chugai Seiyaku Kabushiki Kaisha_20100107

Chugai Seiyaku Kabushiki Kaisha patents


Recent patent applications related to Chugai Seiyaku Kabushiki Kaisha. Chugai Seiyaku Kabushiki Kaisha is listed as an Agent/Assignee. Note: Chugai Seiyaku Kabushiki Kaisha may have other listings under different names/spellings. We're not affiliated with Chugai Seiyaku Kabushiki Kaisha, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Chugai Seiyaku Kabushiki Kaisha-related inventors


Method for evaluating coagulation ability of blood specimen, and reagent, reagent kit and device to be used therein

The present invention relates to a method for evaluating coagulability of a blood specimen obtained from a subject to whom a substance having a coagulation factor VIII-substituting activity is administered. The present invention also relates to a reagent for blood coagulation analysis, a reagent kit for blood coagulation analysis, and... Chugai Seiyaku Kabushiki Kaisha

A combination of two or more anti-c5 antibodies and methods of use

The present invention provides a combination of two or more isolated or purified anti-C5 antibodies, wherein the isolated or purified anti-C5 antibodies bind to an epitope within the beta chain or alpha chain of C5 and wherein the isolated or purified anti-C5 antibodies to be combined do not compete with... Chugai Seiyaku Kabushiki Kaisha

Novel therapeutic agent for septicemia, and a screening for same

The present invention provides a therapeutic agent for sepsis and/or septic shock and a method for screening for the therapeutic agent. The present invention relates to a therapeutic agent for sepsis and/or septic shock comprising an Arid5A inhibitor as an active ingredient. The present invention also relates to a method... Chugai Seiyaku Kabushiki Kaisha

Method for measuring reactivity of fviii

The inventors produced substances that neutralize the activity of a bispecific antibody having an activity of functionally substituting for FVIII, and undertook the construction of methods for measuring the reactivity of FVIII that can ensure accuracy even in the presence of this bispecific antibody. As a result, the inventors discovered... Chugai Seiyaku Kabushiki Kaisha

Combination drug

The present invention relates to a drug that is for treating or preventing cancer, that is effective in the treatment of cancer, and that comprises a combination of an ALK inhibitor and a VEGF inhibitor. The present invention also relates to a method for treating or preventing cancer and a... Chugai Seiyaku Kabushiki Kaisha

Novel hemopoietin receptor protein, nr10

The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was... Chugai Seiyaku Kabushiki Kaisha

Anti-c5 antibodies and methods of use

An objective of the invention is to provide anti-C5 antibodies and methods of using the same. The invention provides anti-C5 antibodies and methods of using the same. In some embodiments, an isolated anti-C5 antibody of the present invention binds to an epitope within the β chain of C5 with a... Chugai Seiyaku Kabushiki Kaisha

Antibody substituting for function of blood coagulation factor viii

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50... Chugai Seiyaku Kabushiki Kaisha

Subcutaneously administered anti-il-6 receptor antibody

The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of... Chugai Seiyaku Kabushiki Kaisha

Method for measuring viscosity of protein solution

The inventors discovered that viscosity of a protein solution can be estimated by measuring the apparent particle size or apparent molecular weight by a small angle X-ray scattering (SAXS) method or X-ray solution scattering method, which enables measurement of small amounts of samples, and then correlating those measurement results with... Chugai Seiyaku Kabushiki Kaisha

Sc(fv)2 site-directed mutant

To solve the above-mentioned problems, the present inventors introduced site-specific mutations into sc(Fv)2 and examined the stabilizing effects on sc(Fv)2. As a result, they succeeded for the first time in significantly increasing the Tm value of sc(Fv)2 by amino acid substitutions. Furthermore, they discovered that sc(Fv)2 is stabilized by introducing... Chugai Seiyaku Kabushiki Kaisha

Modified antibody constant region

The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region... Chugai Seiyaku Kabushiki Kaisha

Methods of modifying antibodies for purification of bispecific antibodies

The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of... Chugai Seiyaku Kabushiki Kaisha

Polypeptide modification purifying polypeptide multimers

The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing... Chugai Seiyaku Kabushiki Kaisha

Method for production of antibody

The present invention provides a method of producing a recombinant antibody efficiently and at low cost. Disclosed is a method of producing an antibody or a fragment thereof, comprising allowing a cell to produce the antibody or the fragment, wherein the cell contains a larger number of copies of an... Chugai Seiyaku Kabushiki Kaisha

Antibody capable of neutralizing substance having activity alternative to function of coagulation factor viii (fviii)

The present inventors attempted to produce antibodies that neutralize the activity of a substance having an activity of functionally substituting for FVIII to be used for the method of measuring the reactivity of FVIII in the presence of a substance having an activity of functionally substituting for FVIII. As a... Chugai Seiyaku Kabushiki Kaisha

Cytotoxicity-inducing therapeutic agent

Novel multi specific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show... Chugai Seiyaku Kabushiki Kaisha

T cell-redirected antigen-binding molecule for cells having immunosuppression function

It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a T cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking T cells with cells having immune... Chugai Seiyaku Kabushiki Kaisha

Methods for treating a disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii

The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to... Chugai Seiyaku Kabushiki Kaisha

Antibody against secreted n-terminal peptide of gpc3 present in blood or c-terminal peptide of gpc3

Disclosed is an antibody against a secreted form of GPC3 capable of detecting a secreted form of glypican 3 (GPC3) in a test sample. It is possible to determine whether a subject suffers from cancer, in particular hepatoma. Also disclosed is an antibody against GPC as well as a cell... Chugai Seiyaku Kabushiki Kaisha

Antibodies with modified affinity to fcrn that promote antigen clearance

The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human FcRn-binding activity at the plasma pH and a lower antigen-binding activity at the early endosomal pH than at the plasma pH; such antibodies can increase the number of antigens to which a single antibody... Chugai Seiyaku Kabushiki Kaisha

Amorphous form of tetracyclic compound

An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.... Chugai Seiyaku Kabushiki Kaisha

Method for identifying epitope on protein

In one aspect, the present invention provides, for example, an improved method for identifying an epitope on a protein, comprising the following steps: (A) contacting a major histocompatibility complex (MHC molecule)-expressing cell differentiated from a stem cell or a progenitor cell derived therefrom with a target protein; (B) isolating a... Chugai Seiyaku Kabushiki Kaisha

Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration

The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.... Chugai Seiyaku Kabushiki Kaisha

Syringe cap, syringe with needle, and prefilled syringe formulation

Provided is a syringe cap including a projection extending in the circumferential direction of a cap body, wherein the projection includes an apex located radially outward of the cap body from the outer circumferential surface of the cap body, a first inclined surface having a starting end located at the... Chugai Seiyaku Kabushiki Kaisha

Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies

Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes... Chugai Seiyaku Kabushiki Kaisha

Antibody substituting for function of blood coagulation factor viii

The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50... Chugai Seiyaku Kabushiki Kaisha

Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient

The inventors successfully produced anti-Epiregulin antibodies showing cross-species reactivity between cynomolgus monkey (non-human animals) and human, anti-Epiregulin antibodies with suppressed chemical degradation, anti-Epiregulin antibodies with lowered isoelectric point, anti-Epiregulin antibodies with increased thermal denaturation midpoint temperature, and anti-Epiregulin antibodies with reduced amount of aggregate by performing appropriate amino acid residue... Chugai Seiyaku Kabushiki Kaisha

Pharmaceutical composition comprising non-ionic surfactants

The present invention relates to a pharmaceutical composition comprising poorly soluble compounds such as BSC class II or IV kinase inhibitors, a process for the preparation thereof and its use in the treatment of diseases, in particular cancer, further particularly in non-small lung cancer.... Chugai Seiyaku Kabushiki Kaisha

Anti-il-6 receptor antibody

The present inventors succeeded in discovering specific amino acid mutations in the variable region, framework region, and constant region of TOCILIZUMAB, and this enables to reduce immunogenicity risk and the heterogeneity originated from disulfide bonds in the hinge region, as well as to improve antigen binding activity, pharmacokinetics, stability under... Chugai Seiyaku Kabushiki Kaisha

Hydantoin derivative-containing pharmaceutical composition

wherein R1, R2, R3, and R4 are as defined in the claims.... Chugai Seiyaku Kabushiki Kaisha

Stable protein-containing preparation containing argininamide or analogous compound thereof

Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.... Chugai Seiyaku Kabushiki Kaisha

Novel crystal of tetracyclic compound

The present invention relates to type II and type III crystals of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile that is a pharmaceutically useful novel crystal.... Chugai Seiyaku Kabushiki Kaisha

Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy

A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or... Chugai Seiyaku Kabushiki Kaisha

Preparation containing tetracyclic compound at high dose

An improved solubility of a pharmaceutical composition or formulation containing a large amount of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile or a salt thereof can be achieved by forming granules of the compound or salt thereof and allowing the granules to be present together with a disintegrating agent.... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022270

Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities

The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022278

Preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient

A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising an interleukin-6 (IL-6) antagonist, for example an antibody directed against IL-6 receptor, an antibody directed against IL-6, an antibody directed against gp130, and the like.... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022287

Immunoactivating antigen-binding molecule

It was discovered that the use of an antigen-binding molecule having a cancer-specific antigen-binding domain, and a TNF superfamily-binding domain or a TNF receptor superfamily-binding domain enables agonist activity against a factor belonging to the TNF superfamily or the TNF receptor superfamily to be exhibited only in the presence of... Chugai Seiyaku Kabushiki Kaisha

01/26/17 / #20170022293

Nucleic acid encoding bispecific antibodies

Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor... Chugai Seiyaku Kabushiki Kaisha

01/12/17 / #20170010270

Method for assaying soluble gpc3 protein

The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.... Chugai Seiyaku Kabushiki Kaisha

01/05/17 / #20170002066

Antibodies with modified affinity to fcrn that promote antigen clearance

The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human FcRn-binding activity at the plasma pH and a lower antigen-binding activity at the early endosomal pH than at the plasma pH; such antibodies can increase the number of antigens to which a single antibody... Chugai Seiyaku Kabushiki Kaisha

01/05/17 / #20170002080

Antibodies with modified affinity to fcrn that promote antigen clearance

The present inventors discovered that antigen uptake into cells is facilitated by an antibody having human FcRn-binding activity at the plasma pH and a lower antigen-binding activity at the early endosomal pH than at the plasma pH; such antibodies can increase the number of antigens to which a single antibody... Chugai Seiyaku Kabushiki Kaisha








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Chugai Seiyaku Kabushiki Kaisha in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Chugai Seiyaku Kabushiki Kaisha with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###